Publications by authors named "Ana Katherine Da Silveira Goncalves De Oliveira"
Associations of the consumption of unprocessed red meat and processed meat with the incidence of cardiovascular disease and mortality, and the dose-response relationship: A systematic review and meta-analysis of cohort studies.
Crit Rev Food Sci Nutr
January 2024
Objectives: The aim of this study was to examine the associations of unprocessed red meat and processed meat consumption with cardiovascular disease (CVD) incidence and mortality, and the dose-response relationship.
Methods: Published literature was retrieved through a structured search of 10 electronic databases: MEDLINE/PubMed, Scopus, SciELO, LILACS, ScienceDirect, Web of Science, Cochrane (CENTRAL), WHOLIS, PAHO and Embase, without language or year of publication restrictions. In addition, we searched the references of published studies.
Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis.
Adv Rheumatol
February 2021
Article Synopsis
- Systemic sclerosis (SSc) is a complex disease that causes skin fibrosis and is often complicated by interstitial lung disease (ILD), typically treated with cyclophosphamide, though its efficacy is debated.
- This paper reviews scientific evidence on the potential benefits of rituximab (RTX) for SSc, analyzing clinical trials published up to May 2020 through systematic searches across multiple databases.
- The review included ten clinical trials, revealing that RTX had significant positive effects on lung function (forced vital capacity) and skin condition (modified Rodnan skin score), suggesting it may be a promising treatment option for SSc-related ILD and skin fibrosis.
Background: Systemic sclerosis (SSc) is a clinically complex and challenging disease, the most frequent complication of which is interstitial lung disease, which leads to a worse prognosis. In this situation, cyclophosphamide is considered the criterion standard for treatment, despite the controversies regarding its efficacy and toxicity. However, studies using rituximab (RTX) have shown that this drug may be a promising therapeutic option.
View Article and Find Full Text PDF